- Results & achievements
AIM 1
Personalised brain metastasis treatment to challenge lethality
With the ultimate goal of challenging brain metastasis-associated lethality, we aim to:
- Stratify brain metastases, considering specificities and genetic signatures, which might or might not be present in the primary tumour.
- Provide in parallel a list of best-scored drugs against each brain metastasis categorised clusters.
- Development of novel computational methodologies for defining optimal treatment schemes.
- Development of a complete and unique brain metastasis multi-omics data portal for the consultation of genomic and associated clinical data to carry out basic and clinical studies helping to advance in the development of therapies for these metastases.
AIM 2
Clinically relevant preventive strategies and brain-compatible immunotherapies to challenge resistance
We will look for the identification of the mechanisms, key molecules, and processes through which tumoral cells cooperate with the microenvironment, revealing new biomarkers or potential drug targets responsible for therapeutic resistance, by:
- Developing strategies to identify patients at high risk of developing relapse post-surgery (local therapy).
- Stratifying the brain metastases that could benefit from combined immunotherapy (resistant to systemic therapy).
AIM 3
Understanding neurocognitive impact to challenge decrease in quality of life (QoL)
Furthermore, as patients with brain metastasis frequently suffer from neurocognitive symptoms caused by a direct effect on brain function, within the network we also aimed to challenge the impact on quality of life, by developing:
- A clinical study incorporating neurocognition evaluation within the RENACER pipeline.
- A detailed multiparametric analysis at the molecular level and based also on advanced imaging data, to define targets for early guided therapies in patients with these symptoms or at predisposition of developing neurocognitive dysfunction.
